Last reviewed · How we verify
ACTIQ®
ACTIQ® delivers fentanyl, a potent opioid analgesic, directly to the oral mucosa for rapid absorption and pain relief.
ACTIQ® delivers fentanyl, a potent opioid analgesic, directly to the oral mucosa for rapid absorption and pain relief. Used for Breakthrough cancer pain in adults who are already receiving and who are tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
At a glance
| Generic name | ACTIQ® |
|---|---|
| Sponsor | Cephalon |
| Drug class | opioid analgesic |
| Target | mu-opioid receptors |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | Phase 2 |
Mechanism of action
Fentanyl acts by binding to the mu-opioid receptors in the central nervous system, which leads to a decrease in the perception of pain and an increase in pain tolerance.
Approved indications
- Breakthrough cancer pain in adults who are already receiving and who are tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain
Common side effects
- Nausea
- Vomiting
- Dizziness
Key clinical trials
- Effectiveness of Percutaneous Neuromodulation vs Pharmacological Treatment in Cancer Patients With Anterior Knee Pain (NA)
- Investigation of the Effects of Two Different Anaesthesia Methods Applied to Patients Scheduled for Arthroscopic Knee Surgery on the Heart (NA)
- Assessment of Endotracheal Tube Temperature Effects in Children Undergoing Adenotonsillectomy (NA)
- Erector Spinae Plane Block vs Quadratus Lumborum Block for Laparoscopic Nephrectomy (NA)
- Modified Thoracoabdominal Nerve Plane Block In Laparoscopic Sleeve Gastrectomy (NA)
- Endobronchial Valve in Tubercular and NTM Pulmonary Cavities. (NA)
- Use of Ultiva ® Associated With Xylocaine ® in the Procedures of Feticide (PHASE3)
- Hemodynamic Monitoring During Craniosynostosis Surgery: Comparing Traditional and Newer Technology Monitors (CRASY-PRAM)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ACTIQ® CI brief — competitive landscape report
- ACTIQ® updates RSS · CI watch RSS
- Cephalon portfolio CI